Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Industry News
Share your love
The Evolution of Intraocular Lenses
Cataract is the most prevalent ophthalmic disease. Treatment of cataracts has been practiced for centuries using various surgical and nonsurgical procedures. However, avoidance of complications and attainment of high-quality postoperative visual rehabilitation were difficult in the years before the introduction…
How to Deal with the Epithelial Herpetic Keratitis
Trifluridine eye drop, acyclovir (ACV) ointment, ganciclovir gel, and oral ACV are still the main therapeutic agents. Cryopreserved amniotic membrane has been recently used as an adjuvant treatment. Resistance to ACV has become a concerning issue. The animal models of…
Retinal Vasculitis: Causes, Symptoms and Management
Retinal vasculitis is an inflammatory condition affecting the blood vessels of the retina. This inflammation can disrupt the normal blood flow, leading to complications that may compromise visual function. Pathophysiology In retinal vasculitis, inflammatory cells such as neutrophils, macrophages, and…
VSY Unveils Enova Advanced EDoF IOL at EPOMEC 2023
VSY Biotechnology, a leading company in ophthalmic innovations, made a notable presence at the 10th Evolving Practice of Ophthalmology Middle East Conference (EPOMEC 2023) in Dubai. The conference, held from 23-25 November, marked a significant moment for VSY Biotechnology as…
FDA Warns Amazon Over Sale of 7 Unapproved Eye Drops
The US Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) has issued a warning letter to e-commerce giant Amazon.com regarding the introduction of unapproved ophthalmic drug products into interstate commerce. The FDA’s warning, delivered in a…
CHMP Backs Bayer’s High-Dose Eylea for Retinal Diseases
Bayer announced on Friday that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of a high-dose formulation of the renowned eye drug Eylea for the treatment of wet age-related macular degeneration and…
VSY Biotechnology to Introduce a Novel Anti-VEGF for AMD
VSY Biotechnology GmbH is proud to announce the groundbreaking development of Varliciment, a revolutionary anti-VEGF agent for the treatment of age-related macular degeneration (AMD). Varliciment distinguishes itself from existing anti-VEGF agents like brolucizumab, namely Novartis’ Beovu, by being non-generic. This…
Blind Canvas Project by Ora and BlindCAN Film Festival
Ora and the BlindCAN Film Festival have jointly unveiled The Blind Canvas Project, an initiative that leverages the capabilities of storytelling and generative artificial intelligence (AI) to cultivate a more profound comprehension of the lives and narratives of individuals affected…
Pantheon Receives $2.5M Funding for Corneal Implant
Pantheon Vision has secured $2.5 million in seed financing from KeraLink International (KLI), a Baltimore-based non-profit organization dedicated to eliminating corneal blindness, with a specific focus on low- and middle-income countries. This funding will launch the development bioengineered corneal implant.…
Ocular Therapeutix Gets FDA Agreement for Wet AMD Trial
Ocular Therapeutix has obtained written FDA approval for the comprehensive design of its pivotal phase 3 clinical trial, known as the SOL trial, which evaluates Axpaxli (axitinib intravitreal implant) for treating wet age-related macular degeneration (AMD) under a Special Protocol…